These seemingly contradictory findings regarding the impact of β-AR agonists and antagonists on VEGF levels suggest that the effects may be mediated through diverse regulation mechanisms depending on the retinal disease and the experimental setting. This evidence concerns the gene ADRB2 and Abnormal retinal morphology.